Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Abstract

Cytotoxic T lymphocyte–associated antigen-4 (CTLA-4) blockade can promote antitumor T cell immunity and clinical responses. The mechanism by which anti–CTLA-4 antibodies induces antitumor responses is controversial. To determine the effects of CTLA-4 blockade on the T cell repertoire, we used next-generation deep sequencing to measure the frequency of individual rearranged T cell receptor β (TCRβ) genes, thereby characterizing the diversity of rearrangements, known as T cell clonotypes. CTLA-4 blockade in patients with metastatic castration-resistant prostate cancer and metastatic melanoma resulted in both expansion and loss of T cell clonotypes, consistent with a global turnover of the T cell repertoire. Overall, this treatment increased TCR diversity as reflected in the number of unique TCR clonotypes. The repertoire of clonotypes continued to evolve over subsequent months of treatment. Whereas the number of clonotypes that increased with treatment was not associated with clinical outcome, improved overall survival was associated with maintenance of high-frequency clones at baseline. In contrast, the highest-frequency clonotypes fell with treatment in patients with short overall survival. Stably maintained clonotypes included T cells having high-avidity TCR such as virus-reactive T cells. Together, these results suggest that CTLA-4 blockade induces T cell repertoire evolution and diversification. Moreover, improved clinical outcomes are associated with less clonotype loss, consistent with the maintenance of high-frequency TCR clonotypes during treatment. These clones may represent the presence of preexisting high-avidity T cells that may be relevant in the antitumor response.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

“…Moreover, CTLA-4 inhibition lowers the threshold required for T cell activation, which results in increased expansion and diversification of circulating, low-avidity T cells 33 ; it also causes an Fc-γR-mediated depletion of T reg cells 34 . In agreement with this, treatment with ipilimumab was found to broaden the TCR repertoire more robustly, within 2 weeks, in those experiencing irAEs than in those without irAEs, and treatment response improved along with the increase in TCR diversity.…”

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

“…Among them, the combination with anti-PD-1 and anti-Cytotoxic T Lymphocyte-associated Antigen-4 (CTLA-4) has shown the best improvement in clinical trials (Hammers et al, 2014;Postow et al, 2015;Wolchok et al, 2013). CTLA-4 blockade induces the expansion of tumor infiltrating T cells inside the tumor tissue, which is critical for the efficacy of combination therapy (Cha et al, 2014). However, anti-CTLA-4 might only expand T cells already present inside tumors.…”

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

“…39 Recently, effects of CTLA-4 blockade on the TCR repertoire in peripheral blood have been investigated. 40 Robert and colleagues reported a diversification of the peripheral T cell pool after treatment with CTLA-4 blocking antibody (tremelimumab) in contrast to healthy donor PBMC.…”